色机身(印有黑色的“TLZ 1”字样)。
存储
储存温度为20°C至25°C(68°F至77°F);允许在15°C至30°C(59°F至86°F)之间进行偏移。[参见USP受控室温]。
请参阅随附的Talzenna完整处方信息: https://labeling.pfizer.com/ShowLabeling.aspx?id=11046
---------------------------------------------------------- Pfizer Talzenna was approved by the US FDA for the treatment of gBRCAm HER2-negative locally advanced or metastatic breast cancer
On October 17, 2018, pharmaceutical giant Pfizer announced that the U.S. Food and Drug Administration(FDA)has approved the targeted anticancer drug Talzenna(talazoparib)for the presence of harmful or suspected harmful germline BRCA mutations (gBRCAm). the treatment of patients with HER2-negative locally advanced or metastatic breast cancer(MBC). In terms of medication, the recommended dose of Talzenna is 1mg orally once a day, taken with or without food.
PRINCIPAL DISPLAY PANEL - 1MG CAPSULE BOTTLE LABEL
Pfizer
NDC 0069-1195-30
Talzenna(talazoparib) capsules
1mg
30 Capsules
Rx only